Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gralla, R.
Right arrow Articles by Delgado, F. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gralla, R.
Right arrow Articles by Delgado, F. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 10:S41-S45, 1999
© 1999 European Society for Medical Oncology

Reviews

Vinorelbine (Navelbine®) in the treatment of non-small-cell lung cancer: Studies with single-agent therapy and in combination with cisplatin

R. Gralla1, P. Harper2, S. Johnson3 and F. M. Delgado4

1 Ochsner Clinic New Orleans, USA
2 Guy's Hospital London
3 Taunton & Somerset Hospital UK
4 Institut de Recherche Pierre Fabre Paris, France

Correspondence to:F. M. Delgado, MD, Institut de Recherche Pierre Fabre, 45 Place Abel Gance, 92654 Boulogne Billancourt Cedex, France, E-mail: miguel_delgado{at}compuserve.com

Initial studies of vinorelbine (Navelbine®) given as a single agent to patients with operable non-small-cell lung cancer (NSCLC) showed that overall response rates of the order of 30% could be obtained with a schedule of 30 mg/m2 given weekly. Although such high levels of response have seldom been obtained when vinorelbine is given alone in one arm of a comparative study, the level of activity is clearly worthwhile and represents a significant improvement over supportive care.

Combination therapy with cisplatin has been highly successful, establishing Vinorelbine as a safe well-tolerated agent which provides considerable activity, and experience from large phase III studies suggests that the combination of vinorelbine and cisplatin could represent a reference schedule against which other therapy should be compared.

cisplatin, non-small-cell lung cancer, vinorelbine


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.